On July 15, 2026, Aurobindo Pharma Limited received FDA approval for its ANDA214872, marking the launch of its generic Etodolac tablets and positioning the company to capture incremental market share in the non-steroidal anti-inflammatory drug segment prior to the patent expiration of the brand. This approval is expected to bolster Aurobindo’s oral solid dosage portfolio while driving incremental revenue growth driven by the anticipated high-volume, generic substitution of the product.